196 related articles for article (PubMed ID: 37271214)
1. Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer.
Gong R; Ma Z; He L; Jiang S; Cao D; Cheng Y
Chem Biol Interact; 2023 Sep; 382():110567. PubMed ID: 37271214
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
3. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
4. Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Sasaki A; Tsunoda Y; Tsuji M; Udaka Y; Oyamada H; Tsuchiya H; Oguchi K
Anticancer Res; 2014 Sep; 34(9):4893-7. PubMed ID: 25202071
[TBL] [Abstract][Full Text] [Related]
5. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
[TBL] [Abstract][Full Text] [Related]
6. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
[TBL] [Abstract][Full Text] [Related]
7. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
8. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
Kawanishi M; Fujita M; Karasawa K
Breast Cancer (Auckl); 2022; 16():11782234221080553. PubMed ID: 35340889
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
10. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
12. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
De Summa S; Pinto R; Pilato B; Sambiasi D; Porcelli L; Guida G; Mattioli E; Paradiso A; Merla G; Micale L; De Nittis P; Tommasi S
Cell Death Dis; 2014 Feb; 5(2):e1076. PubMed ID: 24556691
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
Zhang J; Yang C; Tang P; Chen J; Zhang D; Li Y; Yang G; Liu Y; Zhang Y; Wang Y; Liu J; Ouyang L
J Med Chem; 2022 May; 65(9):6803-6825. PubMed ID: 35442700
[TBL] [Abstract][Full Text] [Related]
14. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
15. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
Xie XF; Wu NQ; Wu JF; Zhang GL; Guo JF; Chen XL; Du CW
Cancer Lett; 2022 Dec; 551():215944. PubMed ID: 36209974
[TBL] [Abstract][Full Text] [Related]
17. MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
Yamamoto M; Jin C; Hata T; Yasumizu Y; Zhang Y; Hong D; Maeda T; Miyo M; Hiraki M; Suzuki Y; Hinohara K; Rajabi H; Kufe D
Cancer Res; 2019 Apr; 79(8):2031-2041. PubMed ID: 30824588
[TBL] [Abstract][Full Text] [Related]
18. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.
Zhang Z; Sun C; Zhang L; Chi X; Ji J; Gao X; Wang Y; Zhao Z; Liu L; Cao X; Yang Y; Mao W
Biomed Pharmacother; 2019 Jan; 109():1541-1546. PubMed ID: 30551406
[TBL] [Abstract][Full Text] [Related]
19. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
20. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
